Relative efficacies: Antimalarials to abatacept - The choice is ours

Journal of Rheumatology

Volumn 36, Issue SUPPL. 82, 2009, Pages 17-24

  Russell, Anthony S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Anti tumor necrosis factor; Biological therapies; Disease modifying antirheumatic drugs; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIMALARIAL AGENT; ATLIZUMAB; BELATACEPT; CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; CYTOKINE RECEPTOR ANTAGONIST; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; ETANERCEPT; GLUCOCORTICOID; GOLD; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADD ON THERAPY; BIOLOGICAL THERAPY; DISEASE COURSE; DRUG CHOICE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MEGADOSE; EARLY DIAGNOSIS; HUMAN; JOINT DESTRUCTION; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; IMMUNOLOGY; PATIENT COMPLIANCE; PATIENT SELECTION; TIME;

ANTIBODIES, MONOCLONAL; ANTIMALARIALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; HUMANS; IMMUNOCONJUGATES; MEDICATION ADHERENCE; PATIENT SELECTION; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67449168364     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090127     Document Type: Review

References (45)

1. Mottonen T, Hannonen P, Korpela M, et al; FIN-RACo Trial Group. FINnish Rheumatoid Arthritis Combination therapy. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002;46:894-898
2. The HERA Study Group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. Am J Med 1995;98:156-168
3. Tsakonas E, Fitzgerald AA, FitzcharlesMA, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 2000;27:623-629 (Pubitemid 30151337)
4. Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology 2007;46:1140-1147 (Pubitemid 47050618)
5. O'Dell JR. Combination DMARD therapy for rheumatoid arthritis: a step closer to the goal. Ann Rheum Dis 1996;55:781-783 (Pubitemid 26392275)
6. O'Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-1170 (Pubitemid 34525821)
7. O'Dell JR, Elliott JR, Mallek JA, et al. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. Arthritis Rheum 2006;54:621-627 (Pubitemid 43228640)
8. Capell HA, Madhok R, Porter DR, et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 2007;66:235-241 (Pubitemid 46226060)
9. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-269 (Pubitemid 38942816)
10. Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J; METGO Study Group. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum 2005;52:1360-1370 (Pubitemid 40663926)
11. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146:406-415 (Pubitemid 351650575)
12. Smolen JS, van der Heijde DM, St. Clair EW, et al; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-710
13. Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-1939.
14. Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-1602 (Pubitemid 32162982)
15. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-1593 (Pubitemid 32162981)
16. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-259 (Pubitemid 29063266)
17. Klareskog L, van der Heijde DM,Wajdula J, Pedersen R, Fatenejad S. Sustained efficacy and safety of etanercept and methotrexate, combined and alone, in RA patients: year 3 TEMPO trial results [abstract]. Ann Rheum Dis 2005;64 Suppl III:59.
18. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-382
19. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-516 (Pubitemid 38530193)
20. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. (Pubitemid 43122183)
21. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45. (Pubitemid 36091645)
22. Emery P, Fleischmann RM,Moreland LW, et al. Golimumab (glm), a new human anti-TNF-alpha monoclonal antibody, administered subcutaneously (sc) every 4 weeks in methotrexate-naïve patients with active rheumatoid arthritis (RA): a randomized, double-blind, placebo-controlled, GO-BEFORE study [abstract]. European League Against Rheumatism 2008; Paris, France; 11-14 June, 2008:THU0138.
23. Keystone E, Genovese MC, Klareskog L, et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody, administered subcutaneously every 4 weeks in patients with active rheumatoid arthritis despite methotrexate: week 24 results of the randomized, double-blind, placebo-controlled, GO-FORWARD study [abstract]. European League Against Rheumatism 2008; Paris, France; 11-14 June, 2008:THU0156.
24. Keystone E, Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-3329
25. Smolen J, Brzezicki J, Mason D, Kavanaugh A. Efficacy and safety of certolizumab pegol in combination with methotrexate (MTX) in patients with active rheumatoid arthritis despite MTX therapy: results from the RAPID 2 study [abstract]. European League Against Rheumatism 2007; Barcelona, Spain; 13-16 June, 2007:THU0202.
26. Kremer JM, Genant HK, Moreland LW, et al. Results of a 2-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methtrexate. Arthritis Rheum 2008;58:953-963 (Pubitemid 351563996)
27. Genant HK, Peterfy CG, Westhovens R, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008;67:1084-1089
28. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009 Jan 5. Epub ahead of print.
29. Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46:1470-1479 (Pubitemid 34620192)
30. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-1103
31. Stahl HD, Szczepanski L, Szechinski J, et al. Rituximab in RA: efficacy and safety from a randomised, controlled trial [abstract]. European League Against Rheumatism 2003; Lisbon, Portugal; 18-21 June, 2003:OP0004.
32. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al; DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-1400
33. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-2204 (Pubitemid 29009378)
34. Kineret™ (anakinra) product monograph. Thousand Oaks, CA: Amgen Inc., December 2006.
35. Jones G, Gu JR, Lowenstein M, et al. Tocilizumab monotherapy is superior to methotrexate monotherapy in reducing disease activity in patients with rheumatoid arthritis: the AMBITION study [abstract]. European League Against Rheumatism 2008; Paris, France; 11-14 June, 2008:OP0131.
36. Bombardieri S, McKenna F, Drosos A, et al. Efficacy and safety of adalimumab (Humira®) in 899 patients with rheumatoid arthritis (RA) who previously failed etanercept and/or infliximab in clinical practice [abstract]. European League Against Rheumatism 2006; Amsterdam, The Netherlands; 21-24 June, 2006:THU0205.
37. Bharadwaj A, Batley M, Hammond A. Switching to other anti TNF agents after 1st anti TNF agent failure in rheumatoid arthritis - is it not the logical option? [abstract]. European League Against Rheumatism 2008; Paris, France; 11-14 June, 2008:AB0277.
38. Smolen J, Kay J, Doyle MK, et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): results of the randomized, double-blind, placebo-controlled GO-AFTER trial [abstract]. European League Against Rheumatism 2008; Paris, France; 11-14 June, 2008:OP0010.
39. Gomez-Reino JJ, Carmona L; BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
40. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumtoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-1123 (Pubitemid 41317434)
41. Keystone E, Aranda R, Becker J-C, Covucci A, Genovese MC. Abatacept provides clinical benefits in rheumatoid arthritis (RA) patients who previously demonstrated a lack of response or no response to one or more anti-TNF therapies [abstract]. Arthritis Rheum 2006;54 Suppl:S406.
42. Cohen SB, Emery P, Greenwald MW, et al; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806
43. Emery P, Keystone E, Tony H, et al. Tocilizumab (TCZ) significantly improves disease outcomes in patients with rheumatoid arthritis whose anti-TNF therapy failed: the RADIATE study [abstract]. European League Against Rheumatism 2008; Paris, France; 11-14 June, 2008:OP0251.
44. Strand V. Longer term benefits of treating rheumatoid arthritis: assessment of radiographic damage and physical function in clinical trials. Clin Exp Rheumatol 2004;22 Suppl 35:S57-64. (Pubitemid 39328356)
45. Bykerk V, Smuczek J, Boire G, et al. Early rheumatoid arthritis (ERA) trials have almost no generalizability to ERA patients: results from a large multi-center cohort [abstract]. Arthritis Rheum 2008;58 Suppl:S761.